Yazar "Ari, Aydan" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim Yok
    Öğe
    Novel Benzimidazole- Platinum(II) Complexes: Synthesis, Characterization, Antimicrobial and Anticancer Activity
    (Elsevier, 2021) Dogan, Umut; Ozcan, Ozge; Alaca, Gizem; Ari, Aydan; Gunnaz, Salih; Yalcin, H. Tansel; Irisli, Sevil
    Three new Platinum complexes (1-3) with 2,6-di-tert-butyl-4-(1-phenyl-1H-benzimidazol-2-yl) phenol (L-1), N, N-dimethyl-4-(1-phenyl-1H-benzimidazol-2-yl) aniline (L-2) and 4-(1H-benzimidazol-2-yl)-N, N-dimethylaniline (L-3) were prepared and characterized by FT-IR, NMR and Elemental analyses. The crystal structures of L-1, 1 and geometrical isomer of 1 (1a) were determined by X-Ray crystallography. The cytotoxic activities of the compounds were tested on against SHSY-5Y and U-87 cell lines. The antimicrobial evaluations of the compounds showed that they have a moderate antimicrobial effect on gram positive and gram negative bacteria. (C) 2020 Elsevier B.V. All rights reserved.
  • Küçük Resim Yok
    Öğe
    Platinum (II) Schiff Base Complexes and their Effects on the Inhibition of Amyloid ?1-42 Aggregation
    (Wiley, 2024) Irisli, Sevil; Guennaz, Salih; Oezcan, Oezge; Ari, Aydan; Maral, Meltem; Erdem, Arzum; Oezel, Derya
    For synthesizing metal-organic molecules with pro-drug properties to prevent the accumulation of amyloid beta (A beta(1-42)), which is a feature of neurodegenerative Alzheimer's disease, two new Schiff bases with imine/amine donors 2-([3,3-diphenylalidene]amino)-N,N-dimethylethane-1-amine and N,N-dimethyl-2-([quinolin-4-ylmethylene]amino)ethane-1-amine, as well as their novel Pt (II) complexes (I and II), were synthesized and characterized via Fourier transform infrared spectroscopy, H-1- and C-13-nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry, and elemental analyses. The spectroscopic data has shown that the ligands are coordinated to the central atom in a chelating manner. Furthermore, the interaction between these complexes and A beta(1-42) was investigated using the electrochemical methods, square wave voltammetry and pencil graphite electrode, while monitoring the changes in the oxidation signal of the Try residue in A beta(1-42). The ability of the compounds to inhibit A beta(1-42) aggregation was investigated using the human neuroblastoma cell line (SH-SY5Y). Complex II could actively inhibit the aggregation of A beta(1-42) at a molar ratio of 1.0/1.0, and its A beta(1-42) aggregation kinetics were fluorometrically determined using thioflavin T. These results were supported by scanning electron microscopy and transmission electron microscopy analyses. Moreover, the interaction of complex II with A beta(1-16) was investigated via H-1-NMR spectroscopy. As a result, it was observed that complex II was effective in inhibiting the aggregation of A beta(1-42) at a molar ratio of 1.0/1.0. This result shows that studies can be conducted on the effects of Schiff base-Pt complexes as potential pro-drugs on Alzheimer's disease.